Regeneron Presses Amgen for Eylea Antitrust Damages Evidence

Regeneron Pharmaceuticals Inc. asked a federal judge to require Amgen Inc. to turn over damages evidence for antitrust counterclaims accusing Regeneron of using patents for its blockbuster Eylea drug to hinder competition from Amgen’s Pavblu biosimilar.

Regeneron’s conditional motion, filed Wednesday in the US District Court for the Northern District of West Virginia, seeks an order requiring Amgen to produce documents and interrogatory responses detailing its alleged damages within seven days if those counterclaims survive Regeneron’s pending dismissal challenges.

Amgen’s antitrust claims, according to Regeneron’s supporting brief, rely primarily on litigation-cost damages tied to “a subset of ...